To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.

Introduced in House

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

House of Representatives